Ming Tan, Ph.D. - Publications

2000 The University of Texas Graduate School of Biomedical Sciences at Houston 
Cell Biology, Molecular Biology, Oncology

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Tan M, Lu J, Zhang Y, Jiang H. Ionic Liquid Confined in Mesoporous Polymer Membrane with Improved Stability for CO₂/N₂ Separation. Nanomaterials (Basel, Switzerland). 7. PMID 28961187 DOI: 10.3390/nano7100299  0.56
2016 Lim S, Smith KR, Lim ST, Tian R, Lu J, Tan M. Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation. Cell & Bioscience. 6: 25. PMID 27087918 DOI: 10.1186/s13578-016-0089-3  0.56
2016 Jin Y, Cai Q, Shenoy AK, Lim S, Zhang Y, Charles S, Tarrash M, Fu X, Kamarajugadda S, Trevino JG, Tan M, Lu J. Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget. PMID 26848621 DOI: 10.18632/oncotarget.7159  0.56
2015 Liu W, Chen Y, Jiang X, Xia M, Yang Y, Tan M, Li X, Rao Z. A Unique Human Norovirus Lineage with a Distinct HBGA Binding Interface. Plos Pathogens. 11: e1005025. PMID 26147716 DOI: 10.1371/journal.ppat.1005025  0.44
2015 Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 189-94. PMID 25452446 DOI: 10.1200/JCO.2014.55.5789  0.44
2015 Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Letters. 356: 156-64. PMID 24732809 DOI: 10.1016/j.canlet.2014.04.001  0.56
2012 Tan M, Yu D, Jin Y, Dou L, Li B, Wang Y, Yue J, Liang L. An information transmission model for transcription factor binding at regulatory DNA sites. Theoretical Biology & Medical Modelling. 9: 19. PMID 22672438 DOI: 10.1186/1742-4682-9-19  0.56
2011 Tan BZ, Jiang F, Tan MY, Yu D, Huang H, Shen Y, Soong TW. Functional characterization of alternative splicing in the C terminus of L-type CaV1.3 channels. The Journal of Biological Chemistry. 286: 42725-35. PMID 21998309 DOI: 10.1074/jbc.M111.265207  0.56
2009 Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 28: 3689-701. PMID 19668225 DOI: 10.1038/onc.2009.229  0.56
2009 Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1326-34. PMID 19228734 DOI: 10.1158/1078-0432.CCR-08-0954  0.56
2007 Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in Experimental Medicine and Biology. 608: 119-29. PMID 17993237  0.56
2006 Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Research. 66: 3764-72. PMID 16585203 DOI: 10.1158/0008-5472.CAN-05-2747  0.56
2006 Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research. 66: 2028-37. PMID 16489002 DOI: 10.1158/0008-5472.CAN-04-4559  0.56
2006 Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 25: 3286-95. PMID 16407820 DOI: 10.1038/sj.onc.1209361  0.56
2005 Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 65: 1858-67. PMID 15753384 DOI: 10.1158/0008-5472.CAN-04-2353  0.56
2004 Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6: 459-69. PMID 15542430 DOI: 10.1016/j.ccr.2004.09.027  0.56
2004 Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6779-88. PMID 15501954 DOI: 10.1158/1078-0432.CCR-04-0112  0.56
2004 Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6: 117-27. PMID 15324695 DOI: 10.1016/j.ccr.2004.06.022  0.56
2002 Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Molecular Cell. 9: 993-1004. PMID 12049736 DOI: 10.1016/S1097-2765(02)00510-5  0.56
1999 Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Research. 59: 1620-5. PMID 10197638  0.56
1998 Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell. 2: 581-91. PMID 9844631  0.56
1998 Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1985-94. PMID 9717829  0.56
1998 Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar A, Yu D. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1065-70. PMID 9563903  0.56
1997 Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research. 57: 1199-205. PMID 9067293  0.56
1996 Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13: 1359-65. PMID 8808711  0.56
Show low-probability matches.